Kynam Capital discloses 4.33% stake in Cogent
Kynam Capital Management and related reporting persons report beneficial ownership of 6,165,223 shares of Cogent Biosciences common stock, representing 4.33% of the class.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kynam Capital Management and related reporting persons report beneficial ownership of 6,165,223 shares of Cogent Biosciences common stock, representing 4.33% of the class. The shares are held with shared voting and dispositive power and no sole authority.
The reporting persons are Kynam Capital Management, LP, Kynam Capital Management GP, LLC, and Yue Tang. They certify the position was acquired and is held in the ordinary course of business, without the purpose or effect of changing or influencing control of Cogent Biosciences.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Who are the reporting persons in the Cogent Biosciences (COGT) Schedule 13G/A?
What is the purpose of Kynam Capital’s Cogent Biosciences (COGT) holdings according to the filing?
What is the event date for Kynam Capital’s Cogent Biosciences (COGT) ownership reported here?
AI-generated analysis. How Rhea-AI works. Not financial advice.